Invesco Pharmaceuticals ETF
$125.12−2.25 (−1.77%)
- Expense ratio
- 0.58%
- Fund size
- $554M
- 1Y return
- +39.1%
- Yield · Last 12 months
- 0.89%
- Holdings
- 28
- Volume · 30D
- 0M sh
- NAV per share
- $126.47
- 52W range
The ETF.net PJP Grade
Score 62 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.CScore 41Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 74Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.AScore 75Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.BScore 61Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.AScore 81Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.BScore 62Category rank
Our read on PJP
BMost pharma ETFs just weight the biggest drugmakers. PJP instead runs a rules-based screen (price and earnings momentum, quality, management action, value) over US pharma names and rebuilds the roughly 30-stock lineup four times a year.
The fund seeks capital appreciation by investing primarily in pharmaceutical companies selected through the Dynamic Pharmaceutical Intellidex Index.
Why people hold it
- Stock-picking logic in an index wrapper: the Dynamic Pharmaceutical Intellidex ranks US pharma companies on price momentum, earnings momentum, quality, management action and value.invesco.com
- Rebalanced and reconstituted quarterly in February, May, August and November, so the roster refreshes on a set schedule rather than drifting with market cap.invesco.com
- Trading since 2005, one of the longest-running pharma funds on the shelf, and it has held a several-hundred-million-dollar asset base with quarterly distributions.
Worth knowing
- The active-style screen carries an active-style price: 0.57% a year, versus 0.35% for XPH, 0.36% for PPH and 0.37% for IHE.
- Thinly traded next to its peer group, so spreads can widen. Limit orders and avoiding the opening and closing minutes matter more here.
- Concentrated by design: roughly 30 US pharma stocks, non-diversified, with no biotech or device diversification to soften a single drug-pipeline shock.invesco.com
PJP Holdings
- Stocks
- 28
- 49%
- GILD
Sectors
- Health Care99.9%
- Financials0.1%
Geography
- United States97.07%
- Ireland2.93%
PJP Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PJP |
|---|---|
| Year to date | +22.8% |
| 1 month | −1.8% |
| 3 months | +13.9% |
| 1 year | +39.1% |
| 3 years | +21.5% |
| 5 years | +11.4% |
| 10 years | +8.1% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PJP |
|---|---|---|
| 2026 YTD | +22.8% | |
| 2025 | +28.0% | |
| 2024 | +9.6% | |
| 2023 | −2.2% | |
| 2022 | −2.2% | |
| 2021 | +14.6% | |
| 2020 | +11.3% |
PJP in the news
ETF.net Research hasn’t filed on PJP yet — coverage lands here as it’s written.
PJP Dividends
- 0.89%
- $1.13
- $0.30 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 21, 2026 | Pays Sep 25, 2026 | $0.30 |
| Jun 22, 2026 | Jun 26, 2026 | $0.27 |
| Mar 23, 2026 | Mar 27, 2026 | $0.31 |
| Dec 22, 2025 | Dec 26, 2025 | $0.25 |
| Sep 22, 2025 | Sep 26, 2025 | $0.24 |
| Jun 23, 2025 | Jun 27, 2025 | $0.27 |
| Mar 24, 2025 | Mar 28, 2025 | $0.27 |
| Dec 23, 2024 | Dec 27, 2024 | $0.22 |
| Sep 23, 2024 | Sep 27, 2024 | $0.20 |
| Jun 24, 2024 | Jun 28, 2024 | $0.21 |
| Mar 18, 2024 | Mar 22, 2024 | $0.17 |
| Dec 18, 2023 | Dec 22, 2023 | $0.19 |
PJP Risk
- 14.9%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.95
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −17.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.46
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PJP Cost
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
4 of the 9 Pharma & Therapeutics funds charge less.